Indications
:
Monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients > 16 years with epilepsy. As adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults & children > 4 years with epilepsy. Adjunctive therapy in the treatment of myoclonic seizures in adults & adolescents > 12 years with Juvenile myoclonic epilepsy. Adjunctive therapy for patients > 16 years with Primary generalized tonic clonic seizure (PGTCS).
Dosage
:
Monotherapy Adult & adolescent > 16 years Initially 250 mg bid, increase to 500 mg bid after 2 weeks. May further increased by 250 mg bid every 2 weeks. Max: 1500 mg bid. Add-on therapy Adult (> 18 years) & adolescent (12-17 years) > 50 kg Initially 500 mg bid. May increase up to 1500 mg bid. Dose titration can be made in steps of 500 mg bid increased or decreased every 2-4 weeks. Children 4-11 years & adolescents (12-17 years) < 50 kg Initially 10 mg/kg bid. May increase up to 30 mg/kg bid. Dose titration can be made in steps of 10 mg/kg bid increased or decreased every 2 weeks. Max: 60 mg/kg/day (children) or 3000 mg/day (adult).